2017

December 14 2017
Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® T

BOTHELL, Washington, 14 December 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how...

December 13, 2017
Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

Bothell, WA, 13 December 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how...

December 11, 2017
Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC

London, UK, 11 December 2017 Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres BTG...

November 27, 2017
Appointment of Non-executive Director

27 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board. Greg has a broad range...

November 16 2017
New consensus guidelines provide specific recommendations for use of Voraxaze® in patients with dela

16 November 2017 BTG plc (LSE: BTG), the global specialist healthcare company, announces the publication of new consensus guidelines for use of Voraxaze® (glucarpidase) in patients with high-dose...

Show 5102550100 per page
Top